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The immunological barrier of the healthy skin is considered to be unified on the whole 
body surface—however, recent indirect findings have challenged this dogma since 
microbial and chemical milieu (e.g., sebum, sweat, and pH) exhibit remarkable differences 
on topographically distinct skin areas. Therefore, in the present study, we performed 
whole transcriptomic and subsequent pathway analyses to assess differences between 
sebaceous gland rich (SGR) and sebaceous gland poor (SGP) regions. Here, we provide 
the first evidence that different skin regions exhibit a characteristic innate and adaptive 
immune and barrier milieu as we could detect significantly increased chemokine (CCL2, 
3, 19, 20, 23, 24) and antimicrobial peptide (S100A7, A8, A9, lipocalin, β-defensin-2) 
expression, altered barrier (keratin 17, 79) functions, and a non-inflammatory Th17/
IL-17 dominance in SGR skin compared to SGP. Regarding pro-inflammatory molecules 
(IL-1α, IL-6, IL-8, IL-33, TNF-α), similarly low levels were detected in both regions. 
Our data may explain the characteristic topographical localization of some immune- 
mediated and autoimmune skin disorders and we also propose that the term “healthy 
skin control sample,” widely used in experimental Dermatology, should only be accepted 
if researchers carefully specify the exact region of the healthy skin (along with the site of 
the diseased sample).
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inTrODUcTiOn
The skin exhibits several essential functions, including its role in formation and maintenance of the 
barrier. Unlike other epithelial surfaces, the skin has two major barrier elements, i.e., the stratum 
corneum and the tight junction layer. Besides these, it is also equipped with a complex network 
of cells and soluble mediators as part of the skin immune system (SIS) (1, 2). The anatomical and 
histological skin structure is characterized by major differences on distinct regions, due to the 
inhomogeneous thickness of the stratum corneum and, moreover, due to variable numbers of 
Abbreviations: AMP, antimicrobial peptide; BP, biological process; DC, dendritic cell; FA, field area; FC, fold change; GO, gene 
ontology; IHC, immunohistochemistry; Ig, immunoglobulin; IL, interleukin; ISP, immune system process; KC, keratinocyte; 
KEGG, Kyoto encyclopedia of genes and genomes; KRT, keratin; MA, Mask area; MF, molecular function; PCA, principal 
component analysis; ROI, region of interest; qRT-PCR, quantitative real-time PCR; SGP, sebaceous gland poor; SGR, sebaceous 
gland rich; SIS, skin immune system; TGF-β, transforming growth factor beta; Th, T helper; TLR, toll-like receptor; TNF-α, 
tumor necrosis factor alpha; TSLP, thymic stromal lymphopoietin.
Table 1 | Characteristics of the studied skin samples of healthy individuals.
healthy individuals/
patients
sex age localization count of 
sebaceous 
glands
sgP skin (n = 10)
SGP 1 M 77 Shin −
SGP 2 M 85 Shin −
SGP 3 F 72 Lower arm −
SGP 4 F 81 Lower arm −
SGP 5 M 40 Lower arm −
SGP 6 F 72 Lower arm −
SGP 7 F 86 Hand −
SGP 8 F 56 Shin −
SGP 9 M 64 Shin −
SGP 10 F 56 Shin −
MEAN AGE ± SD 68.9 ± 14.8
sgr skin (n = 10)
SGR 1 F 77 Heary scalp +
SGR 2 M 62 Mandibula ++
SGR 3 F 57 Nose +++
SGR 4 F 61 Nose +++
SGR 5 F 42 Scapula ++
SGR 6 F 38 Chin ++
SGR 7 M 56 Shoulder +++
SGR 8 M 47 Heary scalp ++
SGR 9 F 19 Face (central part) +++
SGR 10 M 66 Face (lateral part) +++
MEAN AGE ± SD 52.5 ± 16.5
Scoring of sebaceous gland count was performed according to the number and size  
of sebaceous glands in the field of view on 10× magnification: samples containing 
n ≤ 1 sebaceous gland were defined as negative (−), those containing n ≥ 3 
sebaceous glands were defined as positive and scored in accordance with the  
area of sebaceous glands in percentage of dermal surface: (+) 5–15%; (++)  
15–30%; and (+++) more than 30%.
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sebaceous, eccrine, and apocrine glands at different body sites, 
resulting diverse chemical milieu on the skin surface. Parallel to 
this varied chemical milieu, the skin microbiota has also been 
shown to exhibit remarkable differences on topographically dis-
tinct skin areas (3, 4); indeed, specific commensal flora have been 
associated with moist, dry, or sebaceous microenvironments.
On the other hand, the immunological barrier of the healthy 
skin is considered to be unified on the whole body surface—albeit 
recent indirect findings have challenged this dogma. In fact, the 
microbiota was shown to exert remarkable influence on the bar-
rier’s immune function (5, 6).
Moreover, our previous study revealed that, similar to the 
aforementioned heterogeneity of the skin microbiota and 
chemical milieu, a fine topographical difference does exist in 
the expression pattern and activity of the SIS between seba-
ceous gland rich and sebaceous gland poor regions (SGR and 
SGP, respectively) of the human skin (7). Indeed, in SGR skin, 
higher, yet still homeostatic, non-inflammatory thymic stromal 
lymphopoietin (TSLP) expression was detected in epidermal 
keratinocytes (KC) which was regulated by linoleic acid, a major 
sebum component. Furthermore, significantly higher number of 
non-activated CD11c+ dendritic cells (DC), CD4+ T cells, and a 
characteristic cytokine expression pattern were detected in these 
areas. According to these results, we hypothesized that SGR skin 
might exhibit a distinct, non-inflammatory immune surveillance 
which is different from that found in SGP skin.
In the present study, as an extended continuation of our 
previous work, we aimed at in-depth analyzing the putative dif-
ferences between SGR and SGP regions. For this, we performed 
comparative transcriptomic and subsequent pathway enrichment 
analyses, together with validation of selected molecules at the 
gene and protein levels. Here, we provide the first evidence that 
significantly enhanced innate [chemokine, antimicrobial peptide 
(AMP)] and distinct adaptive [dominant T helper (Th17) pres-
ence] immune responses and altered barrier [keratin (KRT) 17, 
79] functions characterize SGR skin compared to SGP. Regarding 
pro-inflammatory cytokines [IL-1α, IL-6, IL-8, IL-33, tumor 
necrosis factor alpha (TNF-α)], similarly low levels could be 
detected in both healthy skin areas which implicates the lack of 
inflammation.
Beyond that our study provide new data on the characteristics 
of SIS and call the attention to the proper  selection of healthy 
skin controls in research, several additional conclusions can also 
be deducted. The fact that region-specific differences exist in the 
composition of SIS allow to consider the pathogenesis of those 
inflammatory and autoimmune skin disorders that favorably 
localize to a given skin area (acne, rosacea, cutaneous lupus to 
SGR skin), from a new aspect. On the other hand, region-specific 
differences in skin barrier formation can underline the probable 
need to develop distinct barrier restoring strategies on distinct 
skin areas.
MaTerials anD MeThODs
skin biopsies
Skin punch biopsies (0.5–1 cm2) were taken from normal skin of 
20 healthy individuals (10 from SGP and 10 from SGR skin sites) 
undergoing plastic surgery after obtaining written, informed con-
sent, according to the Declaration of Helsinki principles (Table 1). 
The study was approved by the local ethics committee of University 
of Debrecen, Hungary. All biopsies were cut into two pieces. For 
IHC, samples were paraffin-embedded, whereas for RT-PCR, sam-
ples were stored in RNAlater (Qiagen, Hilden, Germany) at −70°C 
until RNA isolation. After hematoxylin and eosin (H&E) staining, 
samples were sorted according to the number of sebaceous glands 
and were defined as SGP skin when containing n ≤ 1 sebaceous 
glands and as SGR skin when containing n ≥ 3 sebaceous glands 
in the field of view on 10× magnification in the microscope.
rna isolation, reverse Transcription,  
and real-time Quantitative Pcr
All samples were homogenized in Tri Reagent solution (Sigma-
Aldrich, Dorset, UK) with Tissue Lyser (QIAGEN) using pre viously 
autoclaved metal beads (QIAGEN), and total RNA was isolated 
from the human skin tissues. The concentrations and purities of the 
RNA samples were measured by means of NanoDrop spectropho-
tometer (Thermo Scientific, Bioscience, Budapest, Hungary), and 
its quality was checked using Agilent 2100 Bioanalyser (Agilent 
Technologies, Santa Clara, CA, USA). In the reverse transcription 
step, 1ug of total RNA were reverse transcribed into comple-
mentary DNA (cDNA) using the high capacity cDNA Archive 
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Kit (Invitrogen, Life Technologies, San Francisco, CA, USA) 
according to the manufacturer’s instructions and the indicated 
thermal protocol. Previously samples are treated with DNase I 
(Applied Biosystems, Foster City, CA, USA). QRT-PCR measure-
ments was carried out in triplicate using pre-designed FAM-MGB 
assays as well as TaqMan® Gene Expression Master Mix ordered 
from Applied Biosystems (Life Technologies). The follow ing prim-
ers were used: PPIA (Hs99999904_m1), CCL2 (Hs00234140_m1), 
CCL3 (Hs00234142_m1), CCL19 (Hs00171149_m1), CCL20 
(Hs00355476_m1), CCL23 (Hs00270756_m1), CCL24 (Hs001-
71082_m1), LCN2 (Hs01008571_m1), LOR (Hs01894962_s1), 
FLG (Hs00856927_g1), LCE1F (Hs00820275_sH), CLDN16 
(Hs00198134_m1), KRT17 (Hs00356958_m1), and KRT79 
(Hs00418343_m1). All reactions were performed with a Light-
Cycler® 480 System (Roche). Relative mRNA levels were calcu-
lated using either the comparative CT or standard curve methods 
normalized to the expression of PPIA mRNA.
rna sequencing (rnaseq) analysis
Complementary DNA library for RNASeq was generated from 
1  µg total RNA using TruSeq RNA Sample Preparation Kit 
(Illumina, San Diego, CA, USA) according to the manufacturer’s 
protocol. Briefly, poly-A tailed RNAs were purified by oligodT-
conjugated magnetic beads and fragmented on 94 C for 8 min, 
then 1st strand cDNA was transcribed using random primers 
and SuperScript II reverse transcriptase (Lifetechnologies, 
Carslbad, CA, USA). Following this step second strand cDNA 
synthesized, double stranded cDNA end repaired and 3′ ends 
adenylated then Illumina index adapters were ligated. After 
adapter ligation enrichment, PCR was performed to amplify 
adapter ligated cDNA fragments. Fragment size distribution 
and molarity of libraries were checked on Agilent BioAnalyzer 
DNA1000 chip (Agilent Technologies, Santa Clara, CA, USA). 
Concentrations of RNASeq libraries were set to 10 nM and 5 
libraries were pooled together before sequencing. Single read 
50 bp sequencing run was performed on Illumina HiScan SQ 
instrument (Illumina, San Diego, CA, USA) and 16–18 mil-
lion reads per sample were obtained. CASAVA software was 
used for pass filtering and demultiplexing process. Sequenced 
reads were aligned to Human Genome v19 using TopHat and 
Cufflinks algorithms and bam files were generated. StrandNGS 
software was used for further statistical analysis. Bam files 
were imported and normalized using DESeq algorithm. To iden-
tify statistically significant gene expression patterns between 
conditions non-parametric Wilcoxon–Mann–Whitney test 
was used.
Library preparations, sequencing and data analysis were 
performed at the Genomic Medicine and Bioinformatics Core 
Facility of University of Debrecen.
RNAseq data have been deposited to Sequence Read Archive 
(SRA) database (https://www.ncbi.nlm.nih.gov/sra) under acces-
sion number SRP126212.
Pathway analyses
To map associated genes to their respective pathways, complex 
interactive pathway analysis was performed using the default 
analysis parameters of Ingenuity Pathway Analysis (IPA) 
software (Qiagen, Valencia, CA, USA) web-based application. 
Our input gene list contained the genes, which showed signifi-
cantly different expression between SGR and SGP groups. The 
goal of the analysis was to predict overrepresented pathways, 
gene networks and upstream regulators (transcription factors, 
cytokines, chemokines), which help to characterize the func-
tional and molecular differences between the two types of skin 
regions. The gene list was imported directly from StrandNGS 
software into the IPA to perform IPA Core Analysis with general 
settings: (1) fold change values were added as associated values to 
the analysis, (2) reference set: Ingenuity Knowledge Base (genes 
only), (3) gene symbols were used as identifiers, (4) species: 
Homo sapiens, (5) relationship to include: direct and indirect, 
(6) p-value cutoff: 0.05, (7.) includes endogenous chemicals, 
and (8) predict: (a) diseases and bio functions: (i) diseases and 
disorders, (ii) molecular and cellular functions, (iii) physiologi-
cal system development and function, (b) canonical pathways, 
(c) molecules, and (d) upstream regulators.
A focused enrichment analysis was also performed on immune 
system-related genes revealed by IPA and those molecules which 
have been detected to be significantly differentially expressed 
by RT-PCR or immunohistochemistry (IHC) in our present 
and previous study (7) by ClueGo (v. 2.3.5) (8) and CluePedia 
(v. 1.3.5) (9) tool kits of Cytoscape (www.cytoscape.org) software 
(v. 3.5.1) (10) using gene ontology (GO) biological process (BP), 
GO immune system process (ISP), GO molecular function (MF), 
Kyoto encyclopedia of genes and genomes (KEGG), and reac-
tome pathways databases. In our strict analysis, only significantly 
(p < 0,05) enriched pathways were visualized with an additional 
criterion that enriched terms should have contained at least nine 
genes from our input gene list. Regarding the statistical approach 
of the enrichment analysis by Cytoscape, a p-value of <0.05 
and kappa coefficient of 0.4 were considered as threshold values 
and correction was performed by Benjamini–Hochberg test.
ihc and routine staining
For IHC analyses, paraffin-embedded sections from patients 
and healthy controls were deparaffinized. Heat-induced antigen 
retrieval was performed and sections were pre-processed with 
H2O2 for 10 min. Sections were stained with antibodies against 
human S100A8 (rabbit polyclonal IgG [HPA024372]: Sigma-
Aldrich), human lipocalin/NGAL [rabbit polyclonal IgG (PA5-
32476): Invitrogen], human CCL2/MCP1 [mouse monoclonal 
IgG1 (NBP2-22115): Novus Biologicals, Littleton, CO, USA], 
human CCL20/MIP-3-α [mouse monoclonal IgG (LS-B7409): 
LifeSpan Biosciences, Seattle WA, USA], human KRT17 [rab-
bit polyclonal IgG (ab53707): Abcam], human loricrin [rabbit 
monoclonal IgG (NBP1-33610): Novus Biologicals], human FLG 
[mouse monoclonal IgG (ab17808): Abcam]. Subsequently, anti-
mouse/rabbit (Dako) HRP-conjugated secondary antibody was 
employed. Before and after incubating with antibodies, washing 
of samples was performed for 5 min, 3 times in each step. Staining 
was detected with the Vector® VIP and ImmPACT™ NovaRED™ 
Kit (VECTOR Laboratories, Burlingame, CA, USA). Sections 
were counterstained with methylene green. The detection of one 
protein was carried out on all sections in parallel at the same time 
to enable us to evaluate comparable protein levels. Positive, Ig, 
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and isotype controls were also used to normalize staining against 
all proteins [mouse IgG (Covalab), rabbit immunoglobulin frac-
tion (Dako)]. Skin specimens were also stained with H&E. Visual 
scoring of sebaceous glands’ count was performed by professional 
pathologist.
statistical analysis
Statistical analyses were performed using GraphPad Prism 
software version 6 (GraphPad Software Inc., San Diego, CA, 
USA). Statistical comparisons of two groups were done using 
the unpaired t-test. Differences between the groups were dem-
onstrated using mean ±  SEM. p values <0.05 were considered 
statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001).
resUlTs
rnaseq and iPa analyses reveal 
Prominent Differences between  
sgr and sgP skin regions
RNA Sequencing
In order to explore the in-depth differences between SGR and 
SGP skin, RNASeq analysis was performed on whole skin lysates 
of 6 SGR and 7 SGP patients.
StrandNGS software was applied to create the heatmap 
(Figure 1A) and the principal component analysis (PCA) figure 
(Figure 1B) of our RNASeq data. The heatmap, which was auto-
matically generated by the software, aims to provide evidence 
on whether the two types of skin regions are distinguished 
based on the gene expression profiles of the samples derived 
from certain regions (SGP or SGR). Importantly, the heatmap 
clearly shows that the two regions are indeed unambiguously 
separated by the software. Similarly, the PCA figure (generated 
also by StrandNGS) also reflects the mentioned distinction 
between the two regions. In the PCA figure, each dot represents 
one individual skin sample, the color of the dots indicates the 
region (SGP or SGR), and the distance between the dots shows 
the level of difference between the gene expression profiles 
of the samples. On the basis of these, it is evident that dots with 
the same color created two distinct groups (red: SGP and blue: 
SGR) and that the distance between the differentially colored 
groups is prominent. Of further importance, the heatmap and 
the PCA figure also indicate that gene expression profiles of the 
samples belonging to the given (SGR or SGP) group were similar 
irrespective of the origin of the specimen in a certain skin region. 
In the heatmap, this can be seen based on the color scheme of the 
samples (red: higher expression, blue: lower expression), while 
in the PCA figure, dots representing one region can be found 
within relatively small distance compared to the dots from the 
other region.
Mann–Whitney non-parametric statistical test (p < 0.05) was 
then performed to determine differential gene expression profiles 
of SGR and SGP samples. With this analysis, 1,082 genes were 
found to be differentially (and significantly) expressed in SGR 
compared with SGP skin; out of these, 672 genes showed higher, 
whereas 411 genes exhibited lower expressions in the SGR tissues 
(Table S1 in Supplementary Material).
Ingenuity Pathway Analysis
Using the IPA software, the above 1,082 genes were then subjected 
to two different types of functional, standard, non-restricted 
pathway analyses: canonical pathway analysis and regulatory 
analysis.
First, we performed a non-restricted canonical pathway 
analysis, which revealed 40 significantly enriched terms (canoni-
cal pathway were automatically arranged by IPA based on the 
level of significance; see Figure S1 in Supplementary Material.). 
Of these 40 canonical pathways, the first 14 in the significance 
ranking list were all related to lipid metabolism (such as LXR/
RXR Activation, FXR/RXR Activation, Stearate Biosynthesis I, 
and so on). This was not surprising at all since the per definition 
anatomical differences (presence or lack of sebaceous glands) of 
the two skin regions predisposed these results. The first (i.e., the 
most significant) pathway exclusively related to the SIS was the 
IL-17 related one (Figure 1C). Besides IL-17 signaling, the only 
pathway which could be partially connected to skin immune 
functions was “LPS/IL-1 mediated inhibition of RXR function.”
Next, regulatory IPA analysis was applied; it revealed eight 
sig naling networks in which both upstream regulators and down-
stream cellular responses were identified in relation to certain 
gene panels. Three of these networks were linked to immune sign-
aling processes and pathways, which also contained IL-17 related 
molecules, such as CCL2, S100A8, and S100A9 (Figure  1D) 
whereas all the other five pathways were somehow related to lipid 
metabolism (Figures S2A–E in Supplementary Material).
Further analysis and Validation strategies
Since, both the two pathway analyses and our previous results 
highlighted that differences do exist in the expression of innate 
and adaptive immune and also permeability barrier molecules 
between SGP and SGR region. These results encouraged us to select 
genes for further RT-PCR validation on an extended number of 
samples (SGP: n = 10, SGR: n = 10) far beyond our RNASeq data. 
Namely, based on literature data regarding the most important 
AMP, chemokine, cytokine, permeability barrier, and adaptive 
immune molecules of SIS five groups of genes were formed: 
(1) AMPs, (2) Chemokines, (3) Barrier genes, (4) Pro-inflammatory 
molecules (Table 2), and (5) T helper-related molecules (Table 3).
Since we were interested in defining whether the results (ten-
dency and level of changes in the expression of selected genes 
between the two regions) of the two mRNA based methods 
(RNASeq and RT-PCR) were similar, mRNA expression levels of 
genes detected by RT-PCR were compared to that of our previous 
RNASeq data set (Tables 2 and 3). The comparison revealed that 
expressions of nearly all of the investigated genes altered in the 
same direction detected by the two distinct methods. Moreover, 
in several cases, on the extended number of samples significant 
differences could be detected by using RT-PCR in spite of the fact 
that expression levels of these certain genes (S100A7, DEFB4B, 
LCN2, CCL20, CCL24, IL-1B, and KRT17) did not differ sig-
nificantly in the RNASeq data set. Notably, the complementary 
nature of the two distinct methods has already been documented 
by presenting, e.g., that RT-PCR was able to detect significant 
gene expression differences where RNASeq indicated only ten-
dencies (11).
FigUre 1 | Continued
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Table 2 | Expressions of innate immune molecules, as assessed by RNASeq 
and quantitative real-time PCR (qRT-PCR), including antimicrobial peptides 
(AMPs), chemokines, pro-inflammatory molecules and barrier genes in SGR and 
SGP skin samples.
aMPs qrT-Pcr rna seq
p sgr/sgP (Fc) p sgr/sgP (Fc)
S100A7 0.002 40.36 0.076 3.14
S100A8 0.028 14.99 0.017 4.28
S100A9 0.021 17.49 0.024 3.50
DEFB4B (hBD-2) 0.0002 UDL in SGP 0.154 2.26
LCN2 0.0003 12.12 0.074 4.02
CAMP 0.329 1.83 0.384 1.41
chemokines qrT-Pcr rna seq
p sgr/sgP (Fc) p sgr/sgP (Fc)
CCL2 0.032 1.78 0.0001 2.13
CCL3 0.037 3.58 0.030 2.64
CCL19 0.005 3.31 0.026 2.96
CCL20 0.047 3.44 0.116 2.77
CCL23 0.013 4.34 0.044 3.24
CCL24 0.038 3.68 0.073 2.32
Pro-inflammatory 
molecules
qrT-Pcr rna seq
p sgr/sgP (Fc) p sgr/sgP (Fc)
TLR2 0.150 3.35 0.209 1.36
TLR3 0.468 1.17 0.027 −1.74
TLR4 0.267 2.29 0.929 −1.04
NLRP3 0.291 1.18 0.389 1.54
IL-1A 0.127 2.35 0.515 1.49
IL-1B 0.003 3.10 0.288 1.80
IL-6 0.120 3.10 0.192 −1.77
IL-8 0.414 2.87 0.429 −1.14
IL-33 0.110 1.36 0.720 1.24
TNFA 0.267 1.87 0.147 2.02
barrier genes qrT-Pcr rna seq
p sgr/sgP (Fc) p sgr/sgP (Fc)
LOR 0.434 −5.53 0.101 −2.30
FLG 0.092 −3.98 0.409 −1.40
LCE1F 0.168 −1.29 0.051 −2.27
CLDN1 0.122 −1.46 0.054 −2.02
KRT17 0.002 4.36 0.103 2.59
KRT79 0.027 2.29 0.005 7.72
Fold change (FC) values are calculated by dividing the expression levels measured in 
SGR by those of SGP (SGR/SGP). The p values of significantly differentially expressed 
genes were highlighted in bold.
CAMP, cathelicidin; CCL, chemokine (C-C motif) ligand; CLDN, claudin; DEFB, defensin 
beta; FLG, filaggrin; IL, interleukin; KRT, keratin; LCE, late cornified envelope; LCN, 
lipocalin; LOR, loricrin; NLR, nod-like receptor; S100, S100 calcium-binding protein; 
SGP, sebaceous gland poor; SGR, sebaceous gland rich; TLR, toll-like receptor; TNF, 
tumor necrosis factor; UDL, under detection limit.
FigUre 1 | RNA Sequencing analyses revealed differences in innate and adaptive immune responses between sebaceous gland poor (SGP) and sebaceous gland 
rich (SGR) skin regions (a) Heat map was created by analyzing genes showing significantly different expression (p < 0.05) between SGR (n = 6) and SGP (n = 7) 
skin. By using StrandNGS software the two sample groups could be distinguished unambiguously based on the level of difference between the gene expression 
profiles of samples. On the heatmap, this can be seen based on the color scheme of the samples (red: higher expression, blue: lower expression). (b) Principal 
component analysis (PCA) of RNASeq data (also generated by StrandNGS) showing all samples. On PCA figure each dots represent one skin sample, the color  
of dots indicate sample type (red: SGP and blue: SGR) and the distance between the dots shows the level of difference between the gene expression profiles of 
samples. (c) On the basis of Ingenuity Pathway Analysis (IPA), when analyzing genes with significantly different expression between SGP and SGR skin, the first  
(i.e., the most significant) pathway exclusively related to the skin immune system (SIS) was the IL-17 related one. Genes marked with purple color were present in 
our gene list subjected to pathway analysis. (D) Regulatory IPA analysis identified three highly overlapping, SIS-related Regulator Effect Networks, in which both 
upstream regulators and downstream cellular responses were identified in relation to certain gene panels. These networks were linked to immune signaling 
processes and pathways, which also contained IL-17 related molecules, such as CCL2, S100A8, and S100A9.
Table 3 | Expressions of T helper-related molecules, as assessed by RNASeq 
and Quantitative real-time PCR (qRT-PCR) in SGR and SGP skin samples.
Th1 markers qrT-Pcr rna seq
p sgr/sgP (Fc) p sgr/sgP (Fc)
IL-12B UDL 1.000 1
TBX21* 0.434 1.11 0.124 1.81
IFNG* UDL 0.937 −1.02
TNFA 0.267 1.87 0.147 2.02
Th2 markers qrT-Pcr rna seq
p sgr/sgP (Fc) p sgr/sgP (Fc)
IL-13* UDL 0.272 −1.45
GATA3* 0.327 1.10 0.399 −1.44
Th22 markers qrT-Pcr rna seq
p sgr/sgP (Fc) p sgr/sgP (Fc)
AHR 0.006 3.48 0.738 1.16
IL-22 UDL 0.292 1.13
Th17 markers qrT-Pcr rna seq
p sgr/sgP (Fc) p sgr/sgP (Fc)
IL-1B 0.003 3.10 0.288 1.80
IL-6 0.120 3.10 0.192 −1.77
IL-23A 0.002 UDL in SGP 0.979 1.01
TGFB1 0.432 −1.21 1.000 1
RORC* 0.300 1.37 0.450 −1.15
IL-10* 0.079 3.26 0.336 1.32
IL-17A* 0.0003 UDL in SGP 1.000 1
CCL20 0.047 3.44 0.116 2.77
Fold change (FC) values are calculated by dividing the expression levels measured in 
SGR by those of SGP (SGR/SGP). The p values of significantly differentially expressed 
genes were highlighted in bold. qRT-PCR expression values of molecules marked with 
asterisk have been published in our previous study (7).
AHR, aryl hydrocarbon receptor; CCL, chemokine (C-C motif) ligand; GATA, GATA-
binding protein; IFN, interferon; IL, interleukin; ROR, RAR-related orphan receptor; SGP, 
sebaceous gland poor; SGR, sebaceous gland rich; TBX, T-box; TGF, transforming 
growth factor; TNF, tumor necrosis factor; UDL, under detection limit.
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Finally, to verify the differential expressions in the two skin 
regions also at the protein level, certain molecules were subjected 
to IHC and image analyses.
Prominent Differences in innate immune 
responses between sgr and sgP skin
Expressions of AMPs Are Significantly Higher in  
SGR Skin
First, we aimed to assess the expressions of AMPs since, besides 
their antibacterial actions, their role as alarmin molecules 
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could also emerge in healthy skin regions. By employing qRT- 
PCR, gene expression levels of S100A7 (psoriasin), S100A8, 
S100A9, human β-defensin-2 [hBD-2 (DEFB4B)] and lipocalin 
(LCN2) were high and significantly increased in SGR skin, 
whereas these molecules only weakly expressed in SGP skin. 
Using RNASeq, expressions of all AMPs were elevated in SGR 
skin; the increase regarding S100A8 and S100A9 was found 
to be significant. Expression of cathelicidin (CAMP) was very 
low both in SGP and SGR samples with a slight tendency 
of increase in SGR skin (Table  2; Figure  2). In the cases of 
S100A8 and LCN2, immunostaining was also performed and 
revealed significantly higher protein levels in SGR samples for 
both AMPs (Figure  3). LCN2 could not be detected in SGP 
samples; in SGR skin, the apical layer of the epidermis and 
sebocytes showed slight positivity and its strongest expression 
was found in follicular KCs. Immunostaining of S100A8 also 
revealed prominent differences. This protein could be detected 
at low levels in SGP skin; however, it was present at high levels 
in the upper layers of epidermal KCs, in follicular KCs and in 
sebocytes of SGR skin.
Expressions of Chemokines Are Significantly  
Higher in SGR Skin
Then, the assessment of certain chemokines (CCL2, CCL3, CCL19, 
CCL20, CCL23, and CCL24), produced by innate immune cells 
(KCs, DCs, macrophages), was performed. In SGP skin, by using 
qRT-PCR, expressions of CCL2, CCL19, and CCL20 were well 
detectable but levels of CCL3, CCL23, and CCL24 were very low. 
Of great importance, qRT-PCR revealed significantly higher lev-
els of all investigated chemokines in SGR skin (Table 2; Figure 2). 
Likewise, prominently—and in the cases of CCL2, CCL3, CCL19, 
and CCL23, significantly—higher expressions of these molecules 
in SGR skin were also verified by RNASeq. We also investigated 
the expressions of CCL2 and CCL20 at the protein level by IHC. 
CCL2 was highly expressed in the sebaceous glands in SGR skin. 
Although the epidermal CCL2 positivity was weak in both skin 
types, image analysis revealed significantly higher expression in 
the SGR region (Figure 3). By IHC, CCL20 could not be detected 
either in KCs or in sebocytes in both skin regions (data not 
shown).
No Significantly Different Expression Patterns 
between SGR and SGP Skin Are Detected  
Regarding Innate Immune System Receptors  
and Pro-inflammatory Cytokines
Since marked regional differences of skin microbiota have been 
described previously (3, 4, 12), we also assessed the expressions of 
well-known molecular sensors of KCs, namely toll-like receptor 
(TLR) 2, TLR3, TLR4, and nod-like receptor 3 (NLRP3). RNASeq 
revealed similar gene expression levels of the investigated 
receptors in SGR and SGP skin except TLR3, which showed a 
significant increase in SGR. qRT-PCR measurements confirmed 
the rather insignificant differences in expressions of the above 
receptors (Table 2).
Next, specific mRNA transcript levels of pro-inflammatory 
cytokines [namely IL-1α, IL-1β, IL-6, IL-8, IL-33, and tumor 
necrosis factor alpha (TNF-α)] were compared. RNASeq data 
showed similar expressions in the two regions. Likewise, qRT-
PCR revealed no significant differences between their mRNA 
levels, except for the significantly higher expression of IL-1β in 
SGR samples (Table 2).
altered barrier gene expression  
in sgr compared to sgP
We were also interested in uncovering the potential differences 
in expressions of key molecules involved in the formation and 
maintenance of the epidermal barrier. By qRT-PCR, expressions 
of loricrin (LOR), late cornified envelope 1 F (LCE1F), claudin 16 
(CLDN16), and filaggrin (FLG) showed tendencies of decreased 
expression in the SGR skin, whilst KRT17 and KRT79 expressed 
at higher levels in the SGR samples (the latter ones were found 
to be significantly higher). The directions of differential expres-
sions were confirmed by RNASeq and, in the cases of KRT79, the 
difference was significant (Table 2; Figure 2). KRT17, LOR, and 
FLG were also investigated at the protein level by IHC. KRT17 
was present in significantly higher levels in SGR skin compared 
to SGP (Figure 3). In SGP skin, it was present in the upper layers 
of the epidermis; by contrast, in SGR samples, its expression was 
detected in the whole epidermis with the highest expression in the 
upper layers. Interestingly, the strongest immunoreactivity was 
found in follicular KCs, although sebocytes also showed notable 
positivity in SGR skin. Regarding FLG and LOR, no significant 
differences were identified between SGP and SGR regions, 
although the expression of LOR showed a tendency of decrease 
in SGR skin. Both proteins could be detected continuously with 
strong positivity in the granular and subcorneal layers of the 
epidermis. In SGR skin, hair follicle KCs also showed FLG- and 
LOR-positivity (Figure 3).
sgr skin is characterized by  
a Th17/il-17 Pathway Dominance
Expressions of Th1, Th2, and Th22 Molecules  
Are Negligible and Similar in the Two Skin Regions
As a next step, we compared different T-cell subsets in SGR 
and SGP skin samples by investigating the expression of their 
signature and maturation cytokines, as well as their transcrip-
tion factors. Gene expressions of molecules characteristic to 
Th1 (IL-12B, TBX21, IFN-γ, TNF-α), Th2 (IL-13, GATA3), and 
Th22 [aryl hydrocarbon receptor (AHR), IL-22] cells were not 
different in the two skin regions. By qRT-PCR analysis, IL-12B 
and IL-22 were undetectable in either area, whereas expression 
of AHR was significantly higher in SGR skin. The qRT-PCR 
investigation of TBX21, IFN-γ, IL-13, and GATA3 was already 
performed in our previous study (7), and was not re-evaluated 
in the current work (indicated in Table 3). To reveal what could 
be responsible for the differential expression of AHR between 
the two skin regions, IHC was also performed. Immunostaining 
of AHR also showed significantly higher protein levels in SGR 
samples; AHR was mainly expressed by KCs in their nucleus, 
but cytoplasmic staining in the epidermis was also detectable. 
A few cells in the dermis were also found positive for AHR 
(Figure 3).
FigUre 2 | Continued
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FigUre 2 | Expression of antimicrobial peptides (AMP), chemokines, and barrier genes in sebaceous gland poor (SGP) and sebaceous gland rich (SGR) regions 
examined by quantitative real-time PCR (qRT-PCR). The graphs show the mean ± SEM of measured mRNA transcript levels (*p < 0.05; **p < 0.01; ***p < 0.001.  
as determined by Mann–Whitney U-test). Abbreviations: CAMP, cathelicidin; CCL, chemokine (C-C motif) ligand; CLDN, claudin; DEFB, defensin beta; FLG, filaggrin; 
KRT, keratin; LCE, late cornified envelope; LCN, lipocalin; LOR, loricrin; S100, S100 calcium-binding protein; SGP, sebaceous gland poor; SGR, sebaceous gland rich.
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Th17-Related Genes Exhibit Higher Expression  
in SGR Skin
Although RNASeq data alone did not reveal significant differ-
ences in the expression of Th17-related genes (IL-1β, IL-6, RORC, 
IL-23A, IL-17A, CCL20, IL-10, and transforming growth factor 
beta), as shown above, the in-depth bioinformatics pathway 
analyses have identified the Th17 pathway as a significantly 
enriched term (Figure  1C). Therefore, we further assessed the 
expression of these Th17-molecules by qRT-PCR. Importantly, in 
perfect agreement with our previous findings (7) which revealed 
significantly higher expression of IL-17A (but not of RORC and 
IL-10) in SGR skin, markedly and significantly (p < 0.05) elevated 
levels of IL-1β, IL-23A, and CCL20 as well as tendency of higher 
expression for IL-6 were detected in SGR compared to SGP 
skin (Table 3).
Focused Pathway analysis revealed the 
central role of il-17 Pathway in sgr skin
As a final step, we performed another in-depth bioinformatics 
pathway analysis with those immune system-related molecules 
which had been shown significantly different expression either at 
the gene level (by RNA Seq or RT-qPCR) or at the protein level 
(by IHC) in our present and previous studies (i.e., AHR, CCL2, 
CCL3, CCL19, CCL20, CCL23, CCL24, CCR8, CD48, CD5, CSF1, 
DEFB4B, FASLG, ICOS, IFITM1, IFRD2, IL1B, IL10, IL10RA, 
IL12A, IL17A, IL18, IL23A, IL24, KRT17, KRT79, LCN2, PPARG, 
S100A7, S100A8, S100A9, SAA1, SAA2, SAA2-SAA4, SELP, 
TLR3, TSLP). The analysis was performed by ClueGo application 
of the Cytoscape software using GO BP, GO ISP, GO MF, KEGG, 
and Reactome Pathways databases.
Importantly, by using ClueGo, the result of IPA analysis could 
be confirmed; indeed, IL-17 signaling pathway was found to be 
one of the most significantly enriched terms. Besides this pathway, 
multiple genes exhibiting roles in cytokine activity, cytokine–
cytokine receptor activity, positive regulation of response to 
external stimulus, leukocyte chemotaxis, etc. were also identified 
among the significantly enriched pathways (Figure  4). These 
data, therefore, further confirmed that characteristic differences 
in activities/levels of the SIS could be defined between SGR and 
SGP skin region of the human body.
DiscUssiOn
In this study, we performed extended and comparative analyses 
of innate and adaptive immune and also of barrier functions 
FigUre 3 | Continued
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FigUre 4 | Data visualization of focused enrichment analysis. Immune system-related genes revealed by Ingenuity Pathway Analysis and those molecules that have 
been detected to be significantly differentially expressed by RT-PCR or immunohistochemistry in our present and previous study were all subjected to a new focused 
enrichment analysis performed by ClueGo application of Cytoscape software. Only significantly (p < 0,05) enriched pathways are shown. Additional criteria of the 
analysis: enriched terms should have contained at least nine genes from our input gene list. Symbols of terms represent different databases [circle: gene ontology 
(GO) Biological Process, triangle: Kyoto encyclopedia of genes and genomes, and parallelogram: GO molecular function]. Different colors represent the relationship 
between the terms based on the similarity of their associated genes (one color represents one group). Terms marked with more colors belong to more groups. 
Similarly, genes marked with more colors belong to more terms. The degree of connectivity between terms (edges) and genes is presented by the thickness of lines.
FigUre 3 | Prominent differences in the expressions of innate immune and barrier molecules between sebaceous gland poor (SGR) and sebaceous gland rich 
(SGP) skin regions. Representative images for immunostaining and quantification of epidermal levels of (a) LCN2, (b) S100A8, (c) CCL2, (D) AHR, (e) LOR,  
(F) FLG, and (g) KRT17 in SGP and SGR skin sections. Images of negative control stainings are shown in the bottom left corner of SGP immunostainings. Size 
bars = 100 µm. The graphs show the mean ± SEM of measured protein levels (*p < 0.05; **p < 0.01; ***p < 0.001, as determined by Mann–Whitney U-test). 
Abbreviations: AHR, aryl hydrocarbon receptor; CCL, chemokine (C-C motif) ligand; FLG, filaggrin; KRT, keratin; LCN, lipocalin; LOR, loricrin; S100, S100 
calcium-binding protein; SGP, sebaceous gland poor; SGR, sebaceous gland rich.
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of SGR and SGP healthy skin, since earlier data challenged the 
unified nature of SIS. During the evaluation, significantly differ-
entially expressed genes between SGR and SGP samples turned 
up in relatively high numbers, considering that two healthy skin 
regions were investigated. Furthermore, IPA canonical pathway 
analysis highlighted the importance of IL-17 signaling in the 
SGR region. These findings empowered/encouraged us to study 
in detail the IL-17-influenced innate immune and barrier milieu 
in the mentioned two healthy skin regions. Indeed, we employed 
complementary techniques and analyzed five molecular group 
characteristics to and markers of various skin functions. Albeit 
the reported data were mostly collected during transcriptomics 
analyses and, to lesser extent, from immunolabeling (hence 
future, detailed proteomics and functional studies are demanded 
and warranted), we found that there are indeed marked immuno-
topographical and barrier differences between the SGP and SGR 
regions of the human skin.
Assessment of expressions of AMPs revealed remarkable 
differences between SGR and SGP skin. AMPs are prominent 
effector mediators of the innate immune system, which have far 
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more functions than their antimicrobial activity as they play reg-
ulatory roles in angiogenesis, wound healing, cell proliferation, 
and differentiation; moreover, they exert immune-modulatory 
actions such as stimulation of cytokine and chemokine produc-
tion (13–16). Previous studies showed that hBD-1, hBD-2, 
hBD-3 and human CAMP were detectable at low levels in the 
differentiated epidermal layers of healthy skin (17, 18), while 
RNase7 was highly expressed by healthy KCs found by IHC (19) 
and S100A7 was considered to be one of the principal AMPs in 
normal skin (20). It must be noted that in these previous investi-
gations, the origin of healthy skin samples has not been specified 
(21–26). Only one workgroup examined the regional presence of 
some AMPs (S100A7, hBD-3, and RNase7) in distinct healthy 
skin area. They found that all these proteins were expressed in 
higher amounts in the forehead (characteristic SGR regions) 
compared to lower leg (characteristic SGP region) shown by 
IHC (27), which data are in perfect agreement with our current 
results. Besides S100A7, hBD-2 and CAMP, S100A8, S100A9, 
and LCN2 were found to be undetectable by both RT-PCR and 
IHC or were not investigated previously in healthy skin (23, 25). 
In our present study, low levels of these AMPs (S100A7, A8, A9, 
CAMP, hBD-2, LCN2) were detected in SGP skin. Importantly, 
expressions of all of them, except CAMP, were found to be 
significantly higher in SGR skin. Moreover, S100A8 and LCN2 
could be identified by IHC in both regions, with a significantly 
higher level in SGR skin.
Our knowledge about the investigated chemokines, mainly 
derived from innate immune cells (28–31) in healthy skin is 
quite incomplete. According to our data, in SGP samples, CCL3, 
CCL23, and CCL24 were hardly measurable, whereas CCL2, 
CCL19, and CCL20 expressions were detected in higher levels. 
Importantly, all six investigated chemokines were highly expressed 
in SGR samples, and their expressions were significantly higher 
compared to SGP samples. Previously, Nakayama et al. described 
a low expression of CCL20 in healthy skin by immunostaining 
without indicating the investigated region, whereas Nagao et al. 
were unable to visualize either CCL2 or CCL20 by immune fluo-
rescent staining (32, 33). We found that albeit sebaceous glands 
showed a prominent staining of CCL2 resulting significantly 
higher CCL2 protein expression in SGR skin, the immunoreac-
tivity of both CCL2 and CCL20 was very low or absent in the 
epidermis. As these chemokines mainly target T  cells and also 
affect DCs and macrophages (26, 28–30), these data correlate well 
with our previous observation that T cells and DCs are present at 
significantly higher numbers in SGR skin (7).
In the case of the most important KC sensors (TLR2, TLR3, 
TLR4, NLRP3) and pro-inflammatory cytokines produced 
mainly by innate immune cells (IL-1α, IL-6, IL-8, IL-33, TNF-α), 
no significant differences were found between SGR and SGP 
skin; these findings were not surprising at all since healthy skin 
samples were compared. The only exception was the significantly 
higher level of IL-1β in SGR skin, which probably plays a role 
in establishing the later discussed Th17/IL-17 cytokine milieu of 
this region (34, 35).
Expressions of the late-terminal epidermal differentiation 
markers (LOR, LCE1F, FLG) as well as of the tight junction 
molecule CLDN16 were mostly lower in SGR than in SGP 
skin (albeit the difference was statistically insignificant); this 
may suggest that the epidermal barrier could be somewhat 
weaker in the SGR regions. Actually, this is supported by 
previous reports showing that the degree of transepidermal 
water loss, the increase of which correlates well with impaired 
barrier functions (36), is higher in characteristic SGR regions 
(different facial sites) vs. characteristic SGP regions (forearm, 
arm) (37, 38). By contrast, mRNA levels of KRT17 and KRT79 
were significantly higher in the SGR skin; moreover, KRT17, 
which is usually expressed in basal cells of epithelia (such as 
in SGP skin), is markedly overexpressed in all layers of the 
epidermis in the SGR regions. Of further importance, previous 
studies have found that cytokines related to Th17/Th22 path-
ways (IL-17, IL-22) were shown to upregulate the epidermal 
expression of KRT17 detected by immunofluorescent staining 
and RT-PCR (39–41) and downregulated the level of LOR at 
the mRNA level detected by gene array (42). Therefore, these 
alterations in barrier molecules of KCs may be the result of the 
later discussed Th17  cell/IL-17 cytokine milieu of SGR skin 
regions.
Of greatest importance, however, expressions of compo-
nents of Th17 signaling [(Th17 maturation cytokines and a 
Th17 effector chemokine) (43)] were markedly and, in multiple 
cases significantly (IL-1β, IL-23A, CCL20) higher in SGR 
skin compared to SGP. These results correlated well with our 
previous data, when we were able to detect significantly higher 
mRNA and protein expression of IL-17A found by RT-PCR 
and IHC (7), thus in this study we could reconfirm the pres-
ence of Th17 cells in SGR skin. Notably, not just the presence, 
but also the influence of IL-17 in SGR skin was observed, since 
the above detailed differences in the expression of AMPs, 
chemokines and barrier molecules between SGR and SGP can 
be explained well by the effect of IL-17. It was previously shown 
that IL-17 can upregulate the cutaneous expressions of IL-1β, 
hBD-2, CAMP, S100A7, S100A8, S100A9, LCN2, CCL2, CCL20 
(24, 42), and KRT17 (39, 41) at the mRNA level detected by 
microarray and RT-PCR as well, whereas it can downregulate 
LOR in KCs (42). Moreover, our focused pathway analysis, 
intended to categorize significantly differentially expressed, 
immune system-related molecules into functional groups, could 
also confirm the important role of these molecules in the main-
tenance of SGR skin region-specific immune milieu. However, 
it should be firmly emphasized that the detected effect of IL-17 
in SGR skin appears to be homeostatic and not inflammatory, 
since the expression of neutrophil chemoattractants (such as 
CXCL1, 3, 5, 6, and 8, as determined by RNASeq analysis in 
this study), the production of multiple pro-inflammatory mol-
ecules (see Table 2), and the degree of neutrophil infiltration 
[see our previous study (7)], was not significant in SGR skin. 
Interestingly, among the pro-inflammatory molecules, IL-1β 
was the only one which exhibited higher expression in SGR; 
we think that the higher IL-1β level can promote Th17  cell 
development and can contribute to IL-17 milieu, as detailed 
previously (44).
Along these lines, we propose that the notable differences 
in skin immune and barrier parameters between SGR and SGP 
regions are connected to the distinctions in the composition of 
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FigUre 5 | Healthy SGR skin is characterized by a non-inflammatory T helper 17 (Th17)/IL-17 milieu. The non-inflammatory Th17/IL-17 milieu of SGR skin, which 
was detected in this study, is combined with significantly altered expression of AMPs (S100A7, A8, A9, hBD-2, and lipocalin), chemokines (CCL2, 3, 19, 20, 23,  
and 24) and barrier molecules (KRT17, KRT79, LOR). From the above molecules S100A7, A8, A9, hBD-2, lipocalin, CCL2, 20, KRT17, and LOR have been proven 
to be IL-17-related (24, 39, 41, 42, 50). By contrast, the inflammatory IL-17 effects, such as the expression of neutrophil chemoattractants (RNA Sequencing 
analysis did not reveal significant differences of CXCL1, 3, 5, 6, 8 expression), neutrophil infiltration [see in our previous study (7)], and the production of pro-
inflammatory cytokines (IL-6, TNF) are not characteristic to this region, suggesting that IL-17 has a distinct, homeostatic role in healthy SGR skin. Among the 
pro-inflammatory molecules, IL-1β (44) was the only one with an increased expression in SGR which may promote Th17 cell development and can contribute  
to IL-17 milieu in SGR skin. Abbreviations: AMP, antimicrobial peptide; CCL, chemokine (C-C motif) ligand; CXCL, chemokine (CXC motif) ligand; DC, dendritic  
cell. IL, interleukin; KRT, keratin; LOR, loricrin; S100, S100 calcium-binding protein, SGR, sebaceous gland rich; TNF, tumor necrosis factor.
microbiota and skin surface micromilieu (e.g., sebum and pH) 
between the two regions, since it is well-known that both sebum 
and skin microbiota can influence the immune functions of cells 
in their microenvironment (45–48). It is also important to keep 
in mind that differences in the composition of the sebum and 
microbiota seen between the two regions develop in an acquired 
manner during puberty. Naik et  al. artificially established a 
microbiota change on mouse skin and observed that the induc-
tion of IL-17A is a relatively conserved response of the skin to 
an encounter with a new commensal, and these T cell responses 
were able to promote skin innate responses (production of 
S100A8, A9) (49). Since a similar, but physiological microbiota 
shift develops on the surface of human skin during puberty, we 
hypothesize that Th17/IL-17 immune milieu in SGR region could 
be the remnant of this SIS adaptation during puberty in SGR skin 
(Figure 5).
In the pathogenesis of immune-mediated inflammatory 
and autoimmune skin disorders SIS plays a crucial role. Some 
of these diseases favorably localize to special skin areas, such 
as acne, rosacea, and cutaneous lupus appear mostly on the 
face, scalp, and chest, which are SGR areas. Since until now the 
composition and activation of the SIS was considered unique 
on the whole body, other causes were investigated in the 
background of the region-specific localization of these disea-
ses (sebum, microbiota, endocrine alterations, sunlight). Our 
present data allow to consider this question from a new aspect 
and raise the possibility that region-specific characteristics of 
SIS can have important commitment in the development of 
the region-specific immune-mediated skin diseases. The non-
inflammatory Th17/IL-17 guided immune and barrier milieu 
of SGR skin probably predispose this area for the development 
of inflammatory Th17 type immune-mediated skin diseases, 
after disruption of steady-state condition, due to change in 
sebum, microbiota or sun exposure and endocrine status. 
Recent data from the literature support this hypothesis, since 
in acne, rosacea, and all forms of cutaneous lupus (DLE, SCLE, 
SLE), one of the major skin infiltrating lymphocyte subsets 
is the inflammatory type Th17 cell population (51–54). Our 
recent data also raise the possibility that disrupted tolerance 
and a switch from non-inflammatory to inflammatory Th17/
IL17 milieu may have special role in the development of SGR 
localized inflammatory skin diseases, since in SGR skin dur-
ing steady-state a homeostatic, probably tolerogenic TSLP epi-
dermal expression was detected while a significant loss of this 
TSLP together with prominent influx of inflammatory DCs 
and inflammatory Th17/Th1  cells with IL-17/interferon-γ 
cytokine milieu were observed during the development of 
rosacea (7).
Taken together, our data call the attention to the pr oper selec-
tion of healthy skin controls in research and also to the 
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